Blog - Latest News

You are here: Home » General Biotechnology » Drug Patent Expirations in November 2012
November 30, 2012
30 Nov 2012

Drug Patent Expirations in November 2012

Drug Patent Expirations for November 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
SAMSCA Otsuka America Pharm tolvaptan 5,258,510 Nov 2, 2012
ALLEGRA ALLERGY Sanofi Aventis Us fexofenadine hydrochloride 6,399,632*PED Nov 11, 2012
ALLEGRA Sanofi Aventis Us fexofenadine hydrochloride 6,187,791*PED Nov 11, 2012
ALLEGRA HIVES Sanofi Aventis Us fexofenadine hydrochloride 6,187,791*PED Nov 11, 2012
CHILDREN'S ALLEGRA ALLERGY Sanofi Aventis Us fexofenadine hydrochloride 6,399,632*PED Nov 11, 2012
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION Sanofi Aventis Us fexofenadine hydrochloride; pseudoephedrine hydrochloride 6,187,791*PED Nov 11, 2012
CHILDREN'S ALLEGRA HIVES Sanofi Aventis Us fexofenadine hydrochloride 6,399,632*PED Nov 11, 2012
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION Sanofi Aventis Us fexofenadine hydrochloride; pseudoephedrine hydrochloride 6,187,791*PED Nov 11, 2012
ALLEGRA ALLERGY Sanofi Aventis Us fexofenadine hydrochloride 6,187,791*PED Nov 11, 2012
ALLEGRA HIVES Sanofi Aventis Us fexofenadine hydrochloride 6,399,632*PED Nov 11, 2012
ALLEGRA Sanofi Aventis Us fexofenadine hydrochloride 6,399,632*PED Nov 11, 2012
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION Sanofi Aventis Us fexofenadine hydrochloride; pseudoephedrine hydrochloride 6,399,632*PED Nov 11, 2012
CHILDREN'S ALLEGRA ALLERGY Sanofi Aventis Us fexofenadine hydrochloride 6,187,791*PED Nov 11, 2012
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION Sanofi Aventis Us fexofenadine hydrochloride; pseudoephedrine hydrochloride 6,399,632*PED Nov 11, 2012
CHILDREN'S ALLEGRA HIVES Sanofi Aventis Us fexofenadine hydrochloride 6,187,791*PED Nov 11, 2012
RAPAFLO Watson Labs silodosin 5,780,485 Nov 13, 2012
RAPAFLO Watson Labs silodosin 5,403,847 Nov 13, 2012
RAPAFLO Watson Labs silodosin 6,015,819 Nov 13, 2012
PEPCID COMPLETE Mcneil Cons calcium carbonate; famotidine; magnesium hydroxide 5,229,137*PED Nov 16, 2012
SURFAXIN Discovery Labs lucinactant 5,407,914 Nov 17, 2012
LAMISIL Novartis terbinafine 5,856,355*PED Nov 18, 2012
LAMISIL AT Novartis terbinafine 5,856,355*PED Nov 18, 2012
LAMISIL Novartis terbinafine 6,005,001*PED Nov 18, 2012
PROSCAR Merck finasteride 5,886,184 Nov 19, 2012
PROPECIA Merck finasteride 5,886,184 Nov 19, 2012
CYCLOSET Veroscience bromocriptine mesylate 5,756,513 Nov 21, 2012
CYCLOSET Veroscience bromocriptine mesylate 5,468,755 Nov 21, 2012
CYCLOSET Veroscience bromocriptine mesylate 5,866,584 Nov 21, 2012
LATISSE Allergan bimatoprost 8,017,655 Nov 27, 2012
LUMIGAN Allergan bimatoprost 8,017,655 Nov 27, 2012
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.
1 Tweets/in General Biotechnology
Get updates by email


 

BiotechBlog’s Editor

Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.

Read More...

Network and Share

Connect on LinkedIn
Join BiotechBlog on LinkedIn
Follow BiotechBlog on Twitter
Share BiotechBlog on LinkedIn  Tweet BiotechBlog on Twitter Email biotechnology policy, regulation, and law

Categories

Recommended Reading

Image of Great Patents: Advanced Strategies For Innovative Growth Companies
Image of Get to Market Now! Turn FDA Compliance into a Competitive Edge in the Era of Personalized Medicine
Image of Building the Case for Biotechnology: Management Case Studies in Science, Laws, Regulations, Politics, and Business
Image of Biotechnology Entrepreneurship From Science to Solutions -- Start-up, Company Formation and Organization, Team, Intellectual Property, Financing, ... Regulatory Affairs, Reimbursement, Exit
Image of Biotechnology Entrepreneurship Bootcamp: Journal of Commercial Biotechnology Special Issue
Image of The Life Science Innovation Roadmap: Bioscience Innovation Assessment, Planning, Strategy, Execution, and Implementation
Image of Revolutions: Paving the Way for the Bioeconomy
Image of Building Biotechnology: Business, Regulations, Patents, Law, Politics, Science

Translator

© Copyright - BiotechBlog — A thinkBiotech product